Theratechnologies Inc T.TH

New Press Release - Theratechnologies Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)

Significant reduction in INSTI-associated VAT accumulation with tesamorelin contrasts with VAT increase in patients taking placebo VAT accumulation observed after 12 months on INSTI-containing regimens, even in the absence of significant weight or body mass index changes Results also show a...read article.

[Trogarzon]

Can they put it on the label and become an HIV NASH drug now.  It must be obvious by now that Egrifta is good for NASH patients in HIV and all others because honestly what's the difference between an HIV liver and a non-HIV one.

[Trogarzon]

No news, good news, bad news with Thera = lower price.  Why because, althought encouraging with all that flying colors data.. it never ever translate into share price appreciation. Why because it never transalte into partnerships or money for shareholders.  For that reason, I hope they are privatised at some multiple of actual price in 2023.  Why does a P3 Nash company like Akero

[Drmrgn]

Hit a high of $2.44 usd in Nasdaq in pre-market, only to fizzle out and drop lower than yesterday.

[Joemare]

They also need the twitter bio pros on the bandwaggon. THERA is an unknown company to retail. Old news. Old story.  But the Tesa story is good. So, the clinical people have meat to discuss 'off-label' use. The research guys have meat to go for a combo trial.  

[Trogarzon]

Oh no they will say.. Oh no we can't say that because it's against the law to saw or eaven think such a thing... while every other company out there finance their research on BS statement we're honest and finance at 0$ on the backof our shareholders.  How care wi'll get a zillion new options on 130% bonus come next year.

[Trogarzon]

In their situation it's at a point where they can't say anything no good.  Waisting money on Trogarzo IM is not a good outcome and Egrifta paper is just that another paper.

[Wino115]

Yes, these are certainly less important that if they can see some decent reponses for SZ, but the Egrifta trial does show very strong scientific evidence --just remember what Akero and others saw, where their placebo arms showed good efficacy in fat reduction and it basically submarined their abilities to hit a stat sig endpoint versus the fat reduction their drug had. In this case, the "do